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Rationale
According to the National Survey on Drug Use and Health (SAMHSA, 2012), 22.2
million Americans were identified as substance dependent. Of those 22.2 million, 1.1 million are
dependent on cocaine, making it the third-most widely abused illicit drug. Cocaine is a strong
psychomotor stimulant that increases levels of dopamine (DA) within the mesocorticolimbic
system, resulting in euphoric effects and sustained feelings of pleasure. Sustained drug use leads
to disruptions in reward and motor centers, resulting in increases of locomotor activity, salience
of drug-related stimuli, and dysfunction in neurotransmitter regulation (Penberthy et al., 2010;
Hyman and Malenka 2001). Recreational use of drugs are attributed to environmental influences,
peer-pressure and are used in an attempt to momentarily alleviate negative mood states (Koob
2009). However, acute use fosters the development of compulsive drug use and behaviors due to
increased hedonic values or genetic vulnerability (Koob 2000; Dong and Nestler 2014).
Sex differences have been well documented with respect to cocaine addiction. Although
males are more likely to use drugs for recreational use, females are at higher risk of developing
physiological consequences from drug use and develop a dependency on drugs at a faster rate
and lower dose and have a higher risk of relapse (Brady and Randall, 1999; Ignjatova and
Raleva, 2009). The difference in vulnerability may stem from dimorphic differences in gonadal
hormones with a particular interest in estrogen. Research has shown high levels of estrogen
facilitate the rewarding effects of cocaine and a faster preference to the cocaine-paired chamber
(Lynch et al., 2001). Upon reaching puberty, females begin to ovulate monthly and synthesize
estrogen during the menstrual cycle. Estrogen levels rise and peak during the follicular and
steadily decrease in the middle of the luteal phase of the menstrual cycle (Evans and Foltin
2010).
Estrogen receptors are concentrated near midbrain dopamine systems such as the ventral
tegmental area (VTA) and serotonergic systems including the raphe nuclei, implicating a critical
role for estrogen in modulation of reward value, cognition and motor functions (Nomura et al.,
2005; Creutz and Kritzer 2002) by regulating the expression of critical enzymes in the synthesis
of neurotransmitters (Gundlah et al., 2005). Estrogen has been implicated in increasing DA firing
rate, fibers and striatal DA release (Becker, 1999) and the subjective effects of cocaine are
reported as “more pleasurable” during the follicular phase, when estrogen is highest (Lukas et
al., 1996). Upregulation of DA processes may result in a more intense vesicle release of DA or
prolonged burst firing of DA axons. This contributes to feelings of reward when presented with a
stimulus.
Different pharmacological agents have been proposed as effective for cocaine addiction.
Some treatments include methamphetamine, levo tetrahydropalmatine, GABAergic medications,
and disulfiram. However, increasing concerns regarding efficacy and side-effects have made it
difficult to begin implementing treatments into rehabilitation clinics. Pharmacological treatments
offer short-term relief but become a liability for abuse and those that are have yet to have their
mechanism determined (Shorter and Kosten, 2011). A second obstacle with current treatments is
relapse rates for cocaine addicts is disconcerting, with nearly a quarter relapsing to cocaine
within the first week of being discharged (DATOS, 2001; Simpson et al., 1999), signaling
treatments have limited efficacy on short-term cognitive dysfunctions but do not treat disrupted
neural circuitry, which persists for years after abstinence and are problematic for the continuation
of improvement in quality of life for recovering addicts (Simpson et al., 2002). Although cocaine
addicts often show similar neural dysfunctions and symptoms, many often suffer from
comorbidities such as psychiatric disorders, poly substance abuse and cardiovascular problems

(Miller and Ries, 2004; Devlin and Henry, 2008). Research into cocaine treatments must also
take this into account, illustrating the complexity and difficulty in developing safe and efficient
cocaine treatments.
One of the more promising pharmacological treatments for cocaine addiction is Nacetylcysteine (NAC). NAC is effective in inhibiting reinstatement of cocaine, cue-induced
reactivity (Moussawi et al., 2009) and successfully reverses cocaine’s plastic effects (McClure et
al., 2014; Reichel and See et al., 2012). NAC has been shown to restore glial GLT-1,
normalizing extracellular glutamate levels in the nucleus accumbens and increasing activation of
metabotropic glutamate receptor 5 (mGluR5) (Reissner et al., 2014), a receptor implicated in
cocaine-seeking behaviors (Schmidt et al., 2013). Studies have demonstrated NAC reduces
elevated glutamate levels (Schmaal et al., 2012) and elevated glutathione levels in astrocytes and
reverses excitotoxicity (Badisa et al., 2015), suggesting NAC reduces increased glutamate levels
associated with impulsivity. In response to viewing slides depicting cocaine and cocaine use,
self-reports from hospitalized subjects given NAC for three days showed a decrease in desire to
use and a lower response to cocaine slides (LaRowe et al., 2007).
Taurine is an essential amino acid that displays several neuropsychopharmacological
roles such as neuromodulator, neurotrophic, and osmomodulatory roles (Wu and Prentice, 2010).
Humans mainly obtain taurine through their diet (Laidlaw et al., 1990). Although taurine is
found in all foods, taurine is highest in meat and shellfish such as clams and mussels and grains
such as beans and nuts. Taurine is also found in many energy drinks, a popular beverage
typically consumed by adolescents and has been shown to have adverse effects on the developing
brain and increasing the risk of future drug abuse (Reissig et al., 2009), although energy drinks
also contain high amounts of caffeine and other stimulants (Aranda and Morlock, 2006). The
potential health effects of these other substances have yet to be determined.
Taurine has been shown to be effective in reducing the neurotoxicity typically induced by
drugs of abuse such as methamphetamine and cocaine through activation of antioxidant and
mTOR signaling pathways (Li et al., 2012; Banerjee et al., 2013). It has been found that
following chronic cocaine infusion, taurine levels in the brain increase, suggesting taurine may
play a neuroprotective role in reducing cell death induced by glutamate-mediated neurotoxicity
(Yablonsky-Alter et al., 2009). Preliminary studies have shown co-administration of taurine and
cocaine reduces cocaine-induced locomotor activity and conditioned place-preference (Banerjee
et al., 2013).
The behavioral paradigm employed in the study is conditioned place preference (CPP), a
behavioral model commonly used to assess the reinforcing properties of a stimulus in the
absence of the stimulus itself (Prus et al., 2009). Using a three chambered apparatus, a drug or
stimulus is paired with an outer chamber while the other outer chamber is the vehicle-paired
chamber. The middle chamber functions as a walkway between both paired-chambers. Peripheral
chambers are distinguished from each other by environmental cues such as rough vs smooth
textures, grid patterns, and color schemes. By conditioning the animals to associate a particular
context with the rewarding effects of a stimulus, the rewarding effects of the stimulus are
extended to the environment, allowing the environment to function as a conditioned stimulus
(Pearce and Bouton, 2001). Although both self-administration and CPP measure the rewarding
value of a stimulus, CPP allows for testing animals in a drug-free state and testing the
motivational effects of drugs (Bardo and Bevins, 2000) .Unlike self-administration, where rats
must learn a task, lever-press, and a single behavior is reinforced while other behaviors are
weakened (Panlilio and Goldberg 2007), CPP relies on the rewarding properties of a stimulus

and the strength of its associability with environmental cues. A second critical difference
between the two paradigms is that distinct neural mechanisms mediate the reinforcing properties
(Corbit and Balleine, 2005), demonstrating that addiction is a complex disorder that is not fully
explained by any one test. Therefore, by using preference as a measurement of the rewarding
strength of the drug, CPP is a reliable indicator of the rewarding value of a stimulus and the
animal’s ability to associate contextual cues with the rewarding stimulus.
The objective of this study is to assess the potential of taurine as an intervention for
substance abuse and to address if sex difference plays a role in the efficacy of taurine in reducing
cocaine preference. Moreover, we also investigated whether gonadal hormones regulate taurine’s
efficacy for reducing cocaine reward.
Methods
Thirty-six intact or gonadectomized (GDX) male and female Sprague-Dawley rats are
divided into four groups (Table 1). All rats were housed in a climate-controlled facility with a
12-h light/dark cycle with ad libitum access to food and water. Housing and care were conducted
in accordance with 1996 Guide for the Care and Use of Laboratory Rats (Institute of Laboratory
Animal Resources on Life Sciences, National Research Council, 1996). Pretreatment injections
of either taurine (100 mg/kg) or saline were administered for two weeks and were injected
intraperitoneal (IP). The volume is based on the animal’s weight, volumes ranged from .35 to .52
mL for males and .25 to .36 mL for females.
After two weeks of pre-treatment, a ten-day CPP behavioral paradigm was employed.
Day 1 of behavior was for habituation. Animals were placed into the middle chamber and are
allowed to freely explore the chamber for 15 minutes. During conditioning (day 2 through day
9), before being placed into the CPP chamber, the animals received two injections of either
hydrochloric cocaine (15 mg/kg), saline, or taurine and are placed into the rough texture chamber
for 30 minutes. On alternate days, all treatment groups received two injections of saline on both
sides of the torso and were placed into the smooth texture chamber for 30 minutes. On the tenth
day, behavior was assessed. Animals were placed into the middle chamber with dividers in place.
The dividers were removed and the animals were allowed to freely explore the chamber for 15
minutes and behavior was recorded. The cohorts of male and female rats were performed at two
different times to avoid phenomenal cues.
Table 1-Description of Pre-treatment and Co-treatment Paradigm for Cohorts
Sex-Hormonal Pre-Treatment
Co-administration
Treatment on
Status
(# of animals)
(# of animals)
Rough Side
Females-Intact Taurine (n = 27) Cocaine+Taurine (n = 9) Coc+Tau
Cocaine+Saline (n = 9)
Coc+Sal
Taurine+Saline (n = 9)
Tau+Sal
Saline (n = 9)
Cocaine+Saline (n = 9)
Coc+Sal
Males-Intact
Taurine (n = 27) Cocaine+Taurine (n = 9) Coc+Tau
Cocaine+Saline (n = 9)
Coc+Sal
Taurine+Saline (n = 9)
Tau+Sal
Saline (n = 9)
Cocaine+Saline (n = 9)
Coc+Sal
Females-OVX Taurine (n = 27) Cocaine+Taurine (n = 9) Coc+Tau
Cocaine+Saline (n = 9)
Coc+Sal
Taurine+Saline (n = 9)
Tau+Sal

Treatment on
Smooth Side
Sal
Sal
Sal
Sal
Sal
Sal
Sal
Sal
Sal
Sal
Sal

Males-GDX

Saline (n = 9)
Cocaine+Saline (n = 9)
Taurine (n = 27) Cocaine+Taurine (n = 9)
Cocaine+Saline (n = 9)
Taurine+Saline (n = 9)
Saline (n = 9)
Cocaine+Saline (n = 9)

Coc+Sal
Coc+Tau
Coc+Sal
Tau+Sal
Coc+Sal

Sal
Sal
Sal
Sal
Sal

Results
Overall, pretreatment of taurine was effective in attenuating cocaine preference in male
and female rodents. However, in females, its efficacy was dependent on whether taurine and
cocaine were co-administered. Two-way ANOVAs were used to determine how treatment
impacted time spent in the paired and unpaired chambers. Planned t-test comparisons were
performed to determine significant differences between the paired and unpaired chambers within
each treatment. Significance was determined by a p < 0.05.
. The control group of intact male rats conditioned to cocaine showed a significant
preference to the cocaine-paired chamber (Figure 1; t-value = 2.35; p = 0.037) compared to the
unpaired chamber. Intact males exposed to a pre-treatment of taurine and conditioned to cocaine
show no significant preference towards either chamber. Pre-treatment of taurine and coadministration of taurine/cocaine further reduces cocaine-preference, showing no significant
differences between time spent in paired and unpaired chambers. . Males that were pre-treated
with taurine and conditioned to taurine did not show a significant preference to the taurine-paired
chamber.
Intact-females form a preference to the cocaine-paired chamber (Figure 2; t-value = 2.16;
p = 0.05) when they are not pre-exposed to taurine. Overall, the two-way ANOVA determined
that intact females do not form a preference to the taurine-paired chamber. Similar to intact
males, taurine pre-treatment reduces cocaine preference in intact females, showing no significant
difference between the time spent in the paired and unpaired chambers. Interestingly, taurine pretreatment and co-administration of taurine/cocaine significantly enhances cocaine preference (tvalue 2.85 = p < 0.01).
GDX-males that were not exposed to taurine form a significant preference to the cocainepaired chamber (Figure 3; t –value = 2.78); p=0.024). A two-way ANOVA revealed that GDX
males pre-treated with taurine did not show any significant preference to the cocaine,
cocaine/taurine or taurine paired chambers when compared to the preference time for the
unpaired chambers.
Finally, and interestingly, a two-way ANOVA revealed a significant interaction in OVXfemales (Figure 4: F (3,62) = 4.11; p < 0.01). OVX females did not show a significant
preference to the cocaine paired chambers under any conditions. Interestingly, OVX females did
establish a significant preference to the taurine-paired chamber, when pre-treated with taurine for
two weeks (t-value = 3.20; p < 0.0064). These significant differences between the females
conditioned to cocaine versus taurine are what are driving the significant interaction, as seen by
the t-test comparisons.

Figure 1

Figure 1: Taurine attenuates cocaine preference in intact male rats. Males conditioned to cocaineonly show a significant preference (*) towards the cocaine paired chamber (p<0.036). Taurine
pre-treatment as well as taurine co-administration diminishes cocaine preference as observed
when there are no significant differences in the time spent in the paired and unpaired chambers.
Pre-tau/tau+sal group do not form a preference towards the taurine-paired chamber.

Figure 2

**

*

Figure 2: Co-administration with taurine enhances cocaine preference in intact females. Pretreatment with taurine decreases cocaine preference; however, co-administration of taurine
enhances preference to the drug-paired chamber in female rats (**; p<0.01). Females conditioned
to pre-sal/coc+sal show a significant preference (*) towards the cocaine-paired chamber. Taurine
pre-treatment attenuates cocaine-preference. Pre-tau/tau+sal group do not form a preference
towards the taurine-paired chamber.

Figure 3

Figure 3: Cocaine preference and taurine efficacy is not testosterone-dependent. GDX males
conditioned to cocaine-only show a significant preference (*) towards the cocaine paired
chamber (p<0.025). GDX males do not form a preference to the taurine-paired chamber. Pretreatment and co-treatment is sufficient to reduce cocaine preference to non-significant levels.

Figure 4

Figure 4: Lack of ovarian hormones results in taurine preference while cocaine preference is not
acquired. A two-way ANOVA revealed a treatment by preference interaction (F (3,62) = 4.11; p
< 0.01). OVX females do not form a preference to the cocaine-paired chamber. However, a
preference to the taurine-paired chamber is formed (p <0.0064).

Discussion
Intact males and females form a preference to the cocaine-paired chamber. Pre-treatment
of taurine is sufficient to attenuate cocaine preference in both intact males and females. Neither
intact male or intact female groups show a preference to the taurine-paired chamber. Taurine pretreatment and co-administration of taurine+cocaine further decreases cocaine preference in intact
males but exacerbates cocaine preference in intact females. OVX females do not show a
significant preference towards the cocaine-paired chamber but, interestingly, do show a
preference to the taurine-paired chamber. There is an interaction in the OVX-females with
treatment and preference . GDX males form a preference to the cocaine-paired chamber but pretreatment and co-administration of taurine reduces cocaine preference to non-significant levels.

Experiment 1: Taurine pre-treatment reduces cocaine preference in intact males
Taurine pre-treatment is sufficient to reduce cocaine preference in males. Coadministration of taurine during conditioning further reduces cocaine preference. Similar results
have been seen in treatments for relapse. NAC, in addition to its effect in glutamatergic systems,
also has been implicated in neurotrophic, antioxidant, and inflammatory pathways (Dean et al.,
2011), in virtue by acting as a glutathione precursor (Asevedo et al., 2014). Rats chronically-fed
ethanol are found to have reduced glutathione in their plasma and tissue, resulting in oxidative
stress and damage to cellular structure and function (Pushpakiran et al., 2004). Simultaneous
taurine administration with ethanol was found to restore glutathione levels, suggesting that
taurine and NAC may work through similar, but different pathways as neuroprotective molecules
in drug-induced toxicity.
Previous biochemical studies done by Banerjee at al. 2013demonstrated taurine injected
directly into the striatum reduced spontaneous locomotor activity and CPP for cocaine. Findings
from this experiment validate these findings. Pre-treatment of taurine is sufficient to reduce
cocaine-preference to non-significant levels and co-administration of taurine reduces it even
further. Studies in the same lab (Chan et al., 2014), found taurine modulates NMDA receptors
through multiple mechanisms including reducing affinity of NMDA for glycine and through
TAG receptors. Yablonsky-Alter et al. found that after chronically-withdrawn rats are given a
cocaine challenge, there is an increase of glutamate release in the striatum but, concurrently,
there is an increase of taurine. Taurine’s inhibition of NMDA may be a mechanism through
which the effect of glutamate-induced neurotoxicity is blunted, providing a self-protection
mechanism against cocaine addiction and excitotoxicity.
Experiment 2: GDX males show the same response to taurine as intact males
GDX males show the same development of preferences as intact males. GDX males form
a preference towards the cocaine-paired chamber (p<.03) but pre-treatment and co-treatment of
taurine reduces cocaine’s rewarding effect. Acute or chronic exogenous administration of
testosterone did not differ in time spent in the cocaine-paired chamber when compared to GDX
males. The finding that GDX males show similar results as intact males (Minerly et al., 2008),
suggests testosterone offers minimum contribution to the rewarding effects of cocaine or taurine.
In terms of locomotion, GDX males did show a transient increase in locomotion, but did not
show a progressive increase of locomotion in response to cocaine sensitization (MenendezDelmestre and Segarra 2011) when compared to intact. However, the GDX+ testosterone
replacement group did show sensitization to cocaine but this effect has not been consistently

found as other studies found testosterone treatment in castrated males does not cause behavioral
sensitization (Forgie and Stewart 1994). In addition, testosterone does not regulate the
dopaminergic release in either the striatum or nucleus accumbens (Becker 2009; Triemstra et al.,
2008), suggesting that unlike estrogen, testosterone does not confer any biochemical facilitatory
effects.
Experiment 3: Taurine pre-treatment and co-administration potentiates cocaine preference in
intact females
In intact females, pre-treatment of taurine is sufficient in reducing cocaine preference. In
the brain, taurine functions as a neurotransmitter and may modulate cocaine’s rewarding effect.
Taurine supplementation has been shown to be effective in reversing and treating the deleterious
physiological effects of chronic ethanol consumption (Chen et al., 2009; Park et al., 2009).
Acamprosate, a glutamatergic neuromodulator, has been recently investigated as a potential
treatment for cocaine addiction. Similar to taurine, acamprosate was first touted as an
intervention treatment for reducing ethanol consumption and ethanol-drinking behavior (Oka et
al., 2013). Recently, acamprosate has been investigated as a potential treatment for cocaine
dependence and reinstatement. Acamprosate inhibited reinstatement of both cocaine-preference
(Mcgeehan and Olive 2006) and self-administration (Bowers et al., 2007). Although its exact
mechanisms remain unknown, similar mechanisms that mediate the efficacy of acamprosate
mediate the effects of taurine through the glutamatergic system (Boothby and Doering 2005).
mGluR5 has been implicated in the compulsive behaviors associated with alcohol (Blednov and
Harris 2008) and cocaine dependence (Reissner et al., 2014), making it an ideal candidate for
drug treatments. Interactions between mGluR5 and estrogen have been shown to facilitate of
cocaine’s rewarding (Peterson et al., 2014) and motor sensitization (Grove-Strawser et al., 2010),
suggesting the receptor may be the driving force between the dimorphic difference in drug
escalation and addiction rates between males and females. Taurine pre-treatment may be
inhibiting the activation of mGluR5 by decreasing calcium-evoked currents (Albinana et al.,
2010) or the binding of estrogen to the receptor.
However, co-administration of taurine exacerbates cocaine preference in intact females.
The intensification of preference may be due to the presence of gonadal hormones, specifically
estradiol. Estradiol has been shown to facilitate the rewarding effects of drugs of abuse such as
cocaine and methamphetamine and may be responsible for the increased vulnerability female’s
display to drugs of abuse. Bobzean et al., (2014) showed that acute estradiol injections in OVX
female rats prior to test for CPP produced a significant preference for the cocaine-paired
chamber, demonstrating a prominent role for estradiol in enhancing cocaine preference. Cocaine
has also been shown to induce increases of estradiol and testosterone in intact females but not
intact males, suggesting a self-renewing effect that contributes to the abuse of cocaine (Mello et
al., 2004).

Experiment 4: OVX females form a preference to the taurine-paired chamber
OVX females do not show a preference to the cocaine-paired chamber. This may be due
to the lack of estrogen present in the body. Van Swearingen et al. (2013) showed that OVX
female rats given a 30mg/kg challenge dose of cocaine do not develop a preference to the
cocaine-paired chamber but when given estradiol replacement injection and then a challenge
dose, a preference is formed. This emergence of preference after estrogen treatment shows that

that the presence of estrogen is required for the formation of cocaine-preference. Bobzean et al.
(2014) has shown OVX females develop preference for the cocaine-paired chamber at 5mg/kg
and 10 mg/kg cocaine doses but not at 2.5 mg/kg and 15 mg/kg despite no difference in
locomotor activity in the treatment groups. This demonstrates a dose-response curve in OVXfemales to cocaine. Moderate doses create a preference but low or high doses may produce
aversive properties to the chamber or may too low a dose to create a substantial rewarding effect
or satiates any cravings in the rats.
The most interesting result is that OVX females form a preference to the taurine-paired
chamber since intact females did not form a preference to the taurine-paired chamber. Loss of
estrogen in females may occur due to surgery or natural cause. Limited studies have shown premature loss of estrogen is accompanied by cognitive defect, primarily in the verbal episodic
memory but there has not been enough studies to substantiate these conclusions (Henderson and
Sherwin, 2007; Henderson 2007). What is true for both conditions is loss of estrogen results in
an increase in anxiety, cognitive defects, and increases in dementia (Brann et al., 2007). The
natural loss of estrogen occurs when women reach menopause, where estrogen levels begin to
decline, resulting in cognitive defects in memory and learning. Taurine may play a role in
reducing the anxiety associated with the decline in estrogen. Furuta et al., (2013) found that 3
week postpartum primiparous rats spent the least time in the open arms of the elevated plus maze
and highest immobility time during the forced swim test. When given estradiol (E2) injections
daily for 6 days, E2 significantly reduced anxiety and depressant actions in the elevated plus
maze and forced swim tests. In addition, administration of E2 directly to the hippocampus and
amygdala decreased anxious and depressive behaviors (Walf and Frye, 2006). This may suggest
that while the presence of estrogen potentiates cocaine’s rewarding effect, its absence creates
negative mood states (Pandaranandaka et al., 2009).
Whirley and Einat (2008) found that taurine administration was not effective in reducing
anxiety and depressive behaviors in mice. However, this disparity may be explained because of
the anxiety phenotypes the mice showcased. McCool and Chappell (2007) initially found
strychnine, a glycine antagonist, reduced anxiety in the elevated plus maze and light/dark box
while taurine’s anxiolytic effect was negligible in intact rats. However, when separated into
“low” anxiety and “high” anxiety groups, taurine showed a significant effect in increasing time
spent in the open arms in “high” anxiety animals, representing a reduction in anxiety. This effect
illustrates that taurine is effective in reducing anxiety in highly anxious animals but not as
effective in low anxiety animals. In accordance with our findings, pre-treatment and coadministration of taurine reduces preference to cocaine, a psychostimulant known to induce high
levels of anxiety (Paine et al., 2002). OVX females, a high anxiety phenotype, do form a
preference to the taurine-paired chamber but intact females do not. Furthermore, taurine has been
shown to be effective as an anti-depressant in diabetic rats, a population known to be at higher
risk for depression (Caletti et al., 2012; Toyoda and Lio, 2013). Studies performed in our lab
have shown taurine reduces freezing in forced swim in intact and OVX females (unpublished
data)
Limitations
The subjective feelings associated with psychostimulants changes with the phases of the
menstrual cycle but with other classes of drugs, this effect is moderate. Taurine may be an
effective prevention model for cocaine but may not be as effective in preventing addiction from
sedatives, ethanol, prescription drugs and benzodiazepines because estrogen has been found to

not alter the physiological and subjective effects of other classes of drugs except for
psychostimulants (Terner and Wit, 2006). Taurine’s preventive effect may only be effective in
drugs that work through DA and its mechanisms such as blocking its reuptake or reversing the
flow through the dopamine transporter (DAT). Terner and Wit also believe estrogen modulates
the subjective effect of psychostimulants because this class of drug has direct actions on DA
processes, while other classes of drugs indirectly alter the DA mechanism. Although many
studies inject exogenous estrogen to portray the rise in estradiol seen in women entering the
follicular phase of the menstrual cycle or in rats entering the diestrus cycle (Caligioni 2009;
Owen Jr., 1975), gonadectomy also excludes other important hormones such as follicle
stimulating hormone, luteinizing hormone, progesterone, and testosterone. There is limited
literature investigating the role of other gonadal hormones which are important in regulating the
normal human physiology and may impact cocaine pharmakinetics and treatment options.
While CPP is a useful tool in measuring reward value, the model does have several
limitations. A concern with CPP is that it involves a cognitive component. CPP evaluates
preferences based of associations animals make between context and the reward (Dixon et al.,
2013). Therefore, it measures an animal’s overall experience with an environment and does not
address an animal’s specific behavioral and physiological response to a drug. CPP is a behavioral
paradigm designed to assess the reward value of a drug by time spent in the paired-chamber and
does not tell us about the reinforcement of a drug.
The behavioral paradigm, self-administration, more closely mimics the human drug
addiction with drugs being immediately administered and better models the compulsive nature of
cocaine addiction (Panlilio and Goldberg) than CPP. Self-administration is a model designed to
reinforce responses through the effects of drugs, leading to behavioral sensitization, a crucial
aspect of addiction seen in the natural world. Self-administration can also be better used to test
drug treatments and produces a more valid predictor of clinical efficacy (O’Connor et al., 2011).

Possible Mechanisms by which Taurine can inhibit cocaine preference
Previous research on taurine has elucidated taurine’s role in physiological and cellular
functions (Schaffer et al., 2010; Hussy et al., 2001) but never in the context of a reward. This
study is the first to test if taurine can act as a rewarding stimulus. Therefore, a pre-tau/tau+sal
group is included to investigate if reductions of cocaine preference are due to the neuroprotective
role of taurine and not because of a competing stimulus. In both intact males and females and
GDX-males, there is no significant preference to the taurine-paired chamber, showing taurine is
not a rewarding stimulus and reductions of cocaine-preference is due to taurine’s
neuromodulatory effects. Therefore, decline of preference in the pre-tau/coc+sal suggests taurine
reduces cocaine’s rewarding effect.
One mechanism through which taurine may reduce cocaine preference is reduction of
stress. Females have also been found to higher levels of corticotrophin-releasing factor receptors,
the main stress hormone, suggesting a higher risk for the effects of stress such as cardiovascular
disease, anxiety, depression, and substance abuse (Bangasser et al., 2010; Valentino et al., 2013).
Deviations from normal corticosteroid levels may produce anxiolytic-like symptoms and
discomfort (McEwen 2007), pushing individuals to self-medicate. Taurine has been implicated in
combining with antioxidants to create a more stable antioxidant to suppress the inflammatory
effects of cytokines (Wojcik et al., 2010). Activation of the hypothalamic-pituitary-adrenal axis
(HPA) axis during bouts of stress release glucocorticoids and catecholamines that suppress the

action of cytokines (Elenkov and Chrousos 2002). During self-administration, plasma
corticosterone levels follow a dose-related curve (Goeders et al., 1998). Cocaine induces anxiety
and panic in humans and animals (Goeders, 2002). It may be taurine reduces the strength of the
negative reinforcement motivation (Koob et al., 2014) or suppress the impact of cytokines (Park
et al., 2009), decreasing the need to alleviate the distress and craving to self-medicate. This
implicates taurine as being a potential treatment for preventing cue-induced drug seeking
behavior, a major cause for recovering addicts to relapse.
Taurine is also a structural analog of GABA and glycine, suggesting that its
neuroprotective role may stem from its activation of GABA and glycine receptors (Horikoshi et
al., 1988). Chronic high-dose of cocaine induces long term potentiation (LTP) in ventral
tegmental area (VTA) neurons and disinhibits VTA DA neurons through inhibition of GABAvoltage-sensitive sodium channels (Liu et al., 2005; Steffensen et al., 2008), enhancing
mesocorticolimbic DA transmission. It is possible midbrain GABA neurons modulate the
hedonic value and salience of cocaine and other drugs of abuse. In disregulated systems, drugseeking behavior and reward value are reinforced, resulting in drug abuse and addiction.
Albinana et al., found acute application of taurine induces a dose-dependent chloride
conductance through GABAA channels and regulates calcium conductance. Medium and high
concentrations of taurine bind to glycine and GABA receptors, respectively, in the basolateral
amygdala, hippocampus, and nucleus accumbens (Jia et al., 2008) as well as inhibit thalamic
relay neurons. Taurine is also transported by the GABA transporter at the blood brain barrier as
well as by its own transporter, (Takanaga et al., 2001), illustrating the importance of taurine in
the CNS. Albinana also found intracellular dialysis of GDP-β-σ inhibited the reduction of
calcium conductance seen by taurine binding, demonstrating taurine modulation on voltagegated calcium channels is mediated by G-protein coupled receptors (GPCR). This mechanism is
poorly understood and future research may be directed to investigate if similar GPCR’s are found
in the rat and human brain.
Current research has been investigating the role of taurine and NMDA receptors and their
role in cocaine addiction. Chan et al., (2014) showed that taurine does interact with NMDA
receptors through multiple mechanisms. Continuing down this avenue, Chan et al., (2015)
elucidated that taurine modulates NMDA activation through interactions with the
GluN1/GluN2B subunit. Blocking of GluN2B NMDA receptors rescued dysfunctional long-term
depression in the oval bed nucleus of the stria terminalis, suggesting an important role of NMDA
receptors in the metaplasticity evoked by cocaine and relapse (deBacker et al., 2015). Since,
taurine inhibits NMDA through GluN2B and GluN2B has been shown to be critical for addiction
and relapse (Yuan et al., 2013) and glutamate has been implicated as the mediator of cocaineinduced reinstatement and relapsing (Cornish and Kalivas, 2000), taurine is a potential candidate
for treatment for substance abuse disorders.
Implications
Taken together, the data suggests taurine is an effective intervention for substance use
disorders but its efficacy is dependent on hormonal status. Taurine’s efficacy is not contingent on
the presence of testosterone as intact and castrated males show similar results. Dimorphic
differences to cocaine and taurine may be due to differing levels of estrogen. Estrogen enhances
NMDA excitatory post synaptic potentials (EPSPs) (Foy et al., 1999) and LTP (Smith and
McMahon 2006). Acute cocaine has been found to increases mesocorticolimbic spine density
and excitatory synapses (Luscher and Malenka 2011), an attribute shared with estrogen

(Srivastava et al., 2008). Cocaine produces hyperactivation of PFC-NAc efferents, leading to
increased salience of drug-associated cues and occurrence of compulsive behaviors and cocaine
use fosters ΔFosB accumulation, resulting in the potentiation of synaptic NMDA insertion in
NAc neurons (Dong and Nestler), a critical reward structure. Taurine pre-treatment inhibits
GluN1/GluN2B subunit, reducing NMDA excitation and decreasing cocaine reward and
preference. However, crossing a certain threshold of taurine levels may reverse its protective
effect and facilitate cocaine’s rewarding effect.
Addiction is a disorder of cognition and behavior and involves the interplay of several
disrupted brain structures and functions. When cocaine-preference is brought to extinction and a
challenge dose is administered, rats still show a significant preference towards cocaine
(Brenhouse and Andersen 2008), demonstrating the presence of disrupted neurocircuitry even
after prolonged, suggesting treatment for drug addicts is a complex process. Progesterone and
exercise have been shown to be effective in reducing the reinstatement of cocaine preference but
this effect is greater in females than males (Zlebnik et al., 2014), indicating the importance of
taking into account and investigating the impact sex differences have on the effectiveness of drug
abuse treatments. Rehabilitation clinics should implement multimodal treatment programs to
address the global disruptions caused by drug abuse. By implementing multimodal programs,
treatments are able to treat drug abuse from multiple facets, treating the myriad of familial,
biological and maladjusted social behaviors associated with drug abuse and tailor specific
treatments for patients. These studies support that taurine is a viable candidate for cocaine
addiction, with potentially few side effects, and, in addition, could be neuroprotective. Further
studies need to be performed to assess how taurine is acting on the mesocorticolimbic circuit to
inhibit cocaine reward.
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